MYDA Advisors’s Denali Therapeutics DNLI Stock Holding History

MYDA Advisors’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-12,000	Closed	-$188K	–	134
2017 Q4	$188K	Buy	+12,000	New	+$216K	0.08%	133

Other funds holding DNLI

Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

MYDA Advisors's DNLI Position: Q1 2018 in Review

MYDA Advisors sold out of Denali Therapeutics (DNLI) in Q1 2018, closing a stake of 12,000 shares — an estimated $188K sold.

MYDA Advisors first reported a position in DNLI in Q4 2017 and held it in 1 quarter. The position peaked at $188K in Q4 2017. 58 funds tracked by Wall St. Rank hold DNLI as of Q1 2018.

MYDA Advisors reported no remaining Denali Therapeutics position as of Q1 2018 after selling out during the quarter.
MYDA Advisors sold 12,000 Denali Therapeutics shares in Q1 2018, an estimated $188K.
MYDA Advisors first reported a position in Denali Therapeutics in Q4 2017 and held it in 1 quarter.
MYDA Advisors's Denali Therapeutics position peaked at $188K in Q4 2017.
58 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2018.

Based on MYDA Advisors's 13F filing for Q1 2018, filed 10 May 2018.